Medicare billing address
CMS Medicare provider billing file
3050 Mack Rd Ste 300Fairfield, OH 45014
CMS public data · NPI 1801273313
CMS public files list billing, prescribing, location, and participation fields for this NPI. Current plan networks, appointment availability, clinical outcomes, and patient-specific medical advice require separate verification.
CMS display name
Jayadev R Mettu, M.B.B.S
Specialty
Credential
M.B.B.S
NPI
1801273313
Primary source state
OH
Data retrieval date
July 27, 2026
Where these numbers come from, and what they cannot tell you
Public CMS records, 2024 reporting year. These are historical Medicare fields, not proof of current coverage, appointment availability, quality, or what someone will pay.
This page shows Medicare billing and Part D prescribing data for Jayadev R Mettu, M.B.B.S from CMS public files. It covers 2024 claims data: services billed, the beneficiary panel, and the most-prescribed Part D drugs. It does not show current coverage, appointment availability, or quality ratings.
A licensed agent, not a call center
Peter Abilla, Licensed Medicare Insurance Sales Agent, NPN 22265186. Bring the doctors and prescriptions that matter to you, then check the details before you enroll.
Medicare participating
Yes
Individual assignment
Yes
Group assignment
Yes
CMS opt-out records
0
When CMS files list more than one address for the same NPI, each address stays tied to the CMS file that reported it.
CMS Medicare provider billing file
3050 Mack Rd Ste 300CMS Doctors & Clinicians file
3050 Mack RdIn the 2024 CMS provider billing file, this NPI had 561 Medicare beneficiaries and 77,010 total services. The average beneficiary age was 75, and the average HCC risk score was 2.
Total Medicare allowed amount
$2,067,428.31
Total Medicare payment amount
$1,645,480.10
Medicare beneficiaries
561
Total services
77,010
These percentages describe the Medicare beneficiary panel in the CMS utilization file. They are not a diagnosis for any individual patient and are not a quality score.
Hyperlipidemia
75%
CMS beneficiary-panel share
Hypertension
75%
CMS beneficiary-panel share
Ischemic heart disease
41%
CMS beneficiary-panel share
Diabetes
39%
CMS beneficiary-panel share
Chronic kidney disease
35%
CMS beneficiary-panel share
Heart failure
31%
CMS beneficiary-panel share
Where these service numbers come from, and what they cannot tell you
Amounts shown are average Medicare-approved amounts per billed unit in CMS records. What a person pays depends on current coverage and cannot be read from this table alone.
| CMS service description | Services | Avg allowed |
|---|---|---|
| Injection, denosumab, 1 mg | 3,240 | $25.99 |
| Injection, ferric derisomaltose, 10 mg | 2,200 | $19.93 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,130 | $0.11 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 856 | $7.57 |
| Blood test, comprehensive group of blood chemicals | 654 | $10.28 |
| Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more | 482 | $84.87 |
| Injection, palonosetron hcl, 25 mcg | 420 | $0.86 |
| Gammaglobulin (immune system protein) measurement | 280 | $9.11 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 277 | $15.56 |
| Injection of drug or substance under skin or into muscle | 253 | $13.35 |
Where these Part D numbers come from, and what they cannot tell you
CMS data reports historical prescription drug events attributed to NPI 1801273313. Formularies, copays, prior authorization, and step therapy rules vary by current coverage.
| Rank | Drug | Generic name | Total claims | 30-day fills | Total drug cost |
|---|---|---|---|---|---|
| 1 | Anastrozole | Anastrozole | 200 | 461.9 | $3,032.22 |
| 2 | Oxycodone Hcl | Oxycodone Hcl | 144 | 144 | $4,387.12 |
| 3 | Eliquis | Apixaban | 128 | 176 | $96,521.32 |
| 4 | Letrozole | Letrozole | 94 | 182 | $1,589.43 |
| 5 | Xarelto | Rivaroxaban | 82 | 122 | $63,344.53 |
| 6 | Morphine Sulfate Er | Morphine Sulfate | 57 | 57 | $1,431.48 |
| 7 | Exemestane | Exemestane | 46 | 86 | $9,033.72 |
| 8 | Acyclovir | Acyclovir | 45 | 63 | $501.09 |
| 9 | Brukinsa | Zanubrutinib | 43 | 43 | $538,820.18 |
| 10 | Dexamethasone | Dexamethasone | 35 | 42.4 | $265.28 |
CMS Part D records are historical aggregate claims data. They do not include current formulary status, pharmacy price, prior-authorization rules, network-directory status, or clinical-outcome data.
Graduation year
2011
Group/practice field
Oncology Hematology Care Inc
Telehealth reported
Not reported
Secondary specialty fields reported by CMS: Internal Medicine.
Verify plan-directory status, drug formulary rules, pharmacy pricing, appointment availability, and clinical questions against current plan documents and the relevant provider or care team.
The numbers above come from CMS public-use files for this NPI. Each link identifies the CMS release used and the retrieval date.